Last reviewed · How we verify
NCT07189754
A Study of Sabroxy™ (Oroxylum Indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns
NA trial testing Sabroxy™ (Oroxylum indicum extract) in Mild Cognitive Impairment (MCI) in 70 participants. Completed in 8 February 2021.
8 February 2021
Quick facts
| Lead sponsor | SF Research Institute, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 2 November 2020 |
| Primary completion | 8 February 2021 |
| Estimated completion | 8 February 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sabroxy™ (Oroxylum indicum extract)
- Placebo
Conditions studied
- Mild Cognitive Impairment (MCI) — all drugs for Mild Cognitive Impairment (MCI) →
- Cognitive Dysfunction, Cognitive Disorder — all drugs for Cognitive Dysfunction, Cognitive Disorder →
- Memory Problems — all drugs for Memory Problems →
Sponsor
SF Research Institute, Inc.
Who can join
Adults 60 to 85, any sex, with Mild Cognitive Impairment (MCI) or Cognitive Dysfunction, Cognitive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is testing whether Sabroxy™ (Oroxylum indicum extract) can improve memory and thinking in older adults who report mild problems with their cognition. The study will also measure levels of a protein in the blood called BDNF (Brain-Derived Neurotrophic Factor), which is linked to brain health. The main questions are: Does taking Sabroxy™ improve memory, focus, and overall cognitive performance compared to placebo (a capsule that looks the same but has no active ingredient)? Does Sabroxy™ increase levels of BDNF in the blood? About 80 participants between the ages of 60 and 85 will take part. All participants will be randomly assigned to receive either Sabroxy™ or placebo twice daily for 12 weeks. Neither the participants nor the researchers will know which group they are in (double-blind design). During the study, participants will: Take one capsule twice daily after meals. Complete computerized cognitive tests (COMPASS), interviews with the Montreal Cognitive Assessment (MoCA), and self-assessment questionnaires on memory and thinking. Provide blood samples to measure BDNF. Attend 4 clinic visits (baseline, week 4, week 8, and week 12). Keep a daily diary to track product use and study compliance. The goal is to see whether Sabroxy™ can safely and effectively support cognitive health in older adults with mild memory concerns.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07189754
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mild Cognitive Impairment (MCI)
Currently open trials in the same condition.
- NCT07516119 — Predicting Pre-dementia · recruiting
- NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting
- NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
- NCT07420426 — Instant Message-delivered Personalised Acceptance and Commitment Therapy (IMPACT) for Neuropsychiatric Symptoms in Perso · NA · recruiting
- NCT07286448 — Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment · NA · recruiting
Other SF Research Institute, Inc. trials
Trials by the same sponsor.
- NCT07441070 — Effect of Ashwagandha Root Extract on Stress, Anxiety, and Sleep Quality in Adults Experiencing Minority Stress · NA · enrolling by invitation
- NCT07441096 — Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women · NA · not yet recruiting
- NCT07441083 — Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness · NA · not yet recruiting
- NCT07441109 — Shatavari Root Extract for Perimenopausal Symptoms · NA · not yet recruiting
- NCT07421596 — An 8-Week Study Evaluating Gut and Digestive Health After Use of a Dietary Supplement System · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07189754 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SF Research Institute, Inc.
- Last refreshed: 24 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07189754.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing